A Phase II Study of Tetrathiomolydate (TM) in patients with breast cancer at moderate to high risk for recurrence

Study Status

Open to Enrollment

Study Description

Patients will take Tetrathiomolydate (TM) pills starting at 4 times a day. The dose and schedule may change depending upon how long it takes to achieve the proper amount of copper depletion in the blood. Patients will be monitored for their copper level and CBC closely (weekly) for the first 4 weeks, then the evaluation of these parameters will stretch out to once every 4 weeks.

The maintenance phase will begin when the patient is on a stable TM dose (three times a day) and they have achieved the target copper level in the blood stream without side effects such as anemia. Patients will take TM for 2 years. If a patient relapses, they will be removed from study.

Disease Status and/or Stage

Breast Cancer at moderate to high risk of recurrence (based on the number of lymph nodes); Stage 4 breast cancer without any evidence of disease

Key Eligibility

Patients must:

  • Have breast cancer
  • Be at moderate to high risk of the tumor coming back
  • Have completed standard treatment and be free of all detectable breast cancer metastases

Principal Investigator

Linda Vahdat, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page